Robotic-surgery leader Intuitive Surgical (NASDAQ: ISRG) reported second-quarter 2026 revenue of $2.89 billion, up 19% year on year from $2.44 billion, as da Vinci procedure volume grew roughly 15% and Ion procedure volume grew about 36%. GAAP net income for the quarter reached $818 million.
468 da Vinci systems placed — 246 of them da Vinci 5
Intuitive placed 468 da Vinci surgical systems in Q2 2026, of which 246 were the next-generation da Vinci 5, versus 395 systems (180 of them da Vinci 5) a year earlier. Higher revenue was driven by growth in procedure volume, higher da Vinci system leasing revenue and an expanded installed base of da Vinci and Ion systems.
Guidance holds a strong 13.5%–15.5% procedure growth outlook for 2026
Management reiterated an expectation of 13.5% to 15.5% da Vinci procedure growth for 2026, a strong outlook despite well-flagged headwinds in some international markets. Instruments and accessories revenue continues to be primarily driven by procedure growth, particularly around the ongoing rollout of da Vinci 5, which is being expanded in both the United States and internationally.
Bellwether for a fast-consolidating surgical-robotics category
Intuitive's print lands as competitors race to close the gap: Medtronic's Hugo RAS system has been building out its US urology label and has additional 510(k) submissions for general and gynecologic indications in flight, while CMR Surgical, Stryker and Johnson & Johnson's Ottava all continue to push new clearances. Recent context from our coverage: the da Vinci 5 telepresence and SimNow 2 rollout in June, the telepresence and force-feedback upgrade earlier in the year, and expanded FDA clearances on da Vinci 5.
Shares fell after hours as investors weighed strong system placements against continued spending on training, service capacity and China market pressures.
Reporting based on Intuitive Surgical's Q2 2026 press release and coverage from Stock Titan, Benzinga and Investing.com.